The ICON study demonstrated a median progression-free survival (PFS) of 17.6 months in patients with relapsed and refractory multiple myeloma (RRMM) who were refractory to lenalidomide, a significant outcome for this difficult-to-treat population.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
